# Cardiovascular outcomes

> Personalized telemedicine: cardiovascular stakes — Personalized telemedicine and semaglutide: SELECT, SUSTAIN-6 and heart-failure research place cardiovascular outcomes in their studied populations.

A medical history changes what a result is worth. These trials make that unusually tangible.

## SELECT and established cardiovascular disease

SELECT enrolled [17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes](https://pubmed.ncbi.nlm.nih.gov/37952131/). Semaglutide reduced major adverse cardiovascular events versus placebo, with a hazard ratio of 0.80 and a 95% confidence interval of 0.72–0.90. The cited result describes a 20% relative risk reduction.

The trial used a composite: a combined outcome comprising cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. That gives the headline its concrete content. These are serious events in a population already living with cardiovascular disease.

The cardiovascular finding is substantial, in my judgement. My enthusiasm is attached to that whole description, including the established disease and the absence of diabetes. Removing those features would make the result sound more universal while making it less useful to the question of an individual person. A personal medical history supplies meaning here; it is doing more than filling out a form.

## SUSTAIN-6

In a different population, [SUSTAIN-6 studied people with type 2 diabetes at high cardiovascular risk](https://pubmed.ncbi.nlm.nih.gov/27633186/). Its combined cardiovascular outcome favoured semaglutide, with a hazard ratio of 0.74. Diabetic-retinopathy complications were more frequent with semaglutide, with a hazard ratio of 1.76.

The [safety review advises retinopathy monitoring when blood glucose is corrected rapidly](https://pubmed.ncbi.nlm.nih.gov/34305810/). That is a safety consideration discussed in the research, rather than a monitoring plan for a reader of this site. The simultaneous cardiovascular and eye findings are what make this paper so difficult to compress honestly.

I resist the urge to let either result cancel the other. A cardiovascular benefit deserves its place in the account, and the eye-complication signal deserves its own. The person with a relevant eye history has a reason to be present in this conversation from the start. Personalization sounds more substantial when it can accommodate a benefit and a concern without pretending they form a single verdict.

## Symptoms in STEP-HFpEF

The trial called [STEP-HFpEF, studied obesity-related heart failure with preserved ejection fraction](https://pubmed.ncbi.nlm.nih.gov/37622681/). Semaglutide improved heart-failure-related symptoms and physical limitations and produced greater weight loss than placebo.

Symptoms and limitations bring the discussion closer to the texture of a day. That change in focus widens the achievement, to my mind. The SELECT result concerns a combined cardiovascular event outcome; this trial also gives symptoms and physical limitations a central place. They answer different questions within cardiovascular research, and each is worth hearing in its own terms.

The accompanying scene is an illustration of ordinary movement, with no treatment story attached to the people in it. Its everyday setting is the point: a useful account of health has room for what doing something feels like, as well as the events a trial records.

![Watercolour of everyday passersby walking and resting on broad steps beside a cobalt wall.](images/ordinary-steps.webp)

*Editorial watercolour of everyday movement; the figures do not represent trial participants.*

## A personal medical history

This is the part of the word personalized that carries the most weight for me. Established cardiovascular disease, diabetes and heart-failure symptoms lead into distinct trial populations and distinct outcomes. A summary that turned them all into an undifferentiated claim about heart health would lose the very circumstances that interest me.

The [reading list](/references) brings the cardiovascular papers together. The [longer treatment evidence](/long-term-weight) adds a further dimension: the future over which someone hopes an improvement will last.

---

I follow semaglutide through published research here; Personalized Telemedicine is an essay site with no medical business behind the name, and nothing on these pages is medical advice.